World

Pakistan's record smog forces people home

Nov 12, 2024

Lahore [Pakistan], November 12: On the streets of Pakistan's second biggest city, smog stings eyes and burns throats. Inside homes, few people can afford air purifiers to limit the damage of toxic particles that seep through doors and windows.
Lahore, a city of 14 million people stuffed with factories, regularly ranks among the world's most polluted cities, but it has hit record levels this month.
Schools have closed in the main cities of Punjab province, of which Lahore is the capital, until November 17 in a bid to lower children's exposure to pollution, especially during the morning commute when it is often at its highest. "The children are constantly coughing; they have constant allergies. In schools we saw that most of the children were falling sick," said Rafia Iqbal, a 38-year-old primary school teacher in the city that borders India.
According to the international Air Quality Index (AQI) scale, an index value of 300 or higher is "hazardous" to health and Pakistan has regularly tipped over 1,000 on the scale. The World Health Organization (WHO) says air pollution can trigger strokes, heart disease, lung cancer and other respiratory diseases. It is particularly punishing for children, babies, and the elderly.
Source: Qatar Tribune

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025